Ipca Laboratories Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹2,388Cr
- +6.3% YoY
- −0.2% QoQ
- Net profit
- ₹307Cr
- +379.7% YoY
- −15.7% QoQ
- Margin
- 20%
- +1 pp YoY
- −2 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
The short version
Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.
From Ipca Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms.
- Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth.
- Unichem, a subsidiary, is expected to grow around 10% in the current financial year.
- U.S. business showed a 14% growth in FY26; continued growth is anticipated next year.
- CIS market expected to grow around 10%-11%; domestic India market around 12%-13%.
- Generic business including U.S. and Europe expected to grow around 12%-13%.
- Launches planned: Ipca to commercialize 6-8 products in FY27; Unichem to launch 5-6 products.
2 more points from Ipca Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Ipca Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Ipca Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from Ipca Laboratories Ltd's call on order book
Create a free account to keep reading this call
Ipca Laboratories Ltd — Quarterly revenue & net profit
Ipca Laboratories Ltd Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 2,388 | 2,247 | +6.3% | 2,392 | -0.2% |
| Operating profit (EBITDA) | 484 | 429 | +12.8% | 533 | -9.2% |
| Operating margin | 20% | 19% | +1 pp | 22% | -2 pp |
| Profit before tax | 404 | 128 | +215.6% | 446 | -9.4% |
| Net profit (PAT) | 307 | 64 | +379.7% | 364 | -15.7% |
| EPS (₹) | 11.79 | 2.67 | +341.6% | 12.86 | -8.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹2.9K Cr, net profit ₹389 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Ipca Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Balaxi Pharma (Q4 FY26)
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Key investor presentation takeaways from Balaxi Pharma's Q4 FY
- Accretion Pharmaceuticals (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Ipca Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Ipca Laboratories Ltd Q4 FY26 results?
Overall consolidated revenue growth guidance for FY27 is around 12% to 13% in INR terms. - Domestic branded formulation business is expected to grow around 12%, with 1%-2% contribution from new products and the balance from price increases and volume growth. - Unichem, a subsidiary, is expected to grow around 10% in the current financial year. - U.S. Domestic branded business is guided to grow around 12% in FY27, with 1-2% from new products and the rest from price and volume increases.
What is Ipca Laboratories Ltd share price analysis?
Ipca Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 32.0 with a market cap of ₹43,997 Cr. Investors should review the full earnings analysis for detailed insights.
Is Ipca Laboratories Ltd planning capital expenditure?
- There is mention of a U.S.
Keep Ipca Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
